Elsevier

Life Sciences

Volume 54, Issue 17, 1994, Pages 1215-1228
Life Sciences

Alternate-day dosing during buprenorphine treatment of opioid dependence

https://doi.org/10.1016/0024-3205(94)00848-5Get rights and content

Abstract

Thirteen opioid-dependent outpatients participated in a double-blind, placebo-controlled, crossover trial. Twenty-one days of daily sublingual buprenorphine administration were compared to 21-days of alternate-day buprenorphine administration where patients received twice their daily maintenance dose every other day with placebo on the interposed day. Observer- and subject-rated measures of oploid agonist and withdrawal effects, pupillary diameter, and dose identifications were collected daily. Ten subjects (77%) completed the study (n=6, 4 mg/70 kg; n=4, 8 mg/70 kg); 8 subjects (62%) participated in a second crossover. Sixteen of seventeen measures of opioid agonist and withdrawal effects obtained during alternate-day administration did not differ significantly from those obtained during daily dosing in the ten subjects completing the study. The only significant difference observed was in subject-rated agonist effects, which were significantly lower during alternate-day than daily administration. No differences were observed between treatments on any measure for the eight subjects completing a second crossover. These data suggest that buprenorphine can be administered safely every 48 hours by doubling the maintenance dose. This alternate-day schedule permits patients to attend the clinic less frequently without the risk of diversion associated with take-home doses, may be cost-effective for programs, and may be useful in settings in which travel to the clinic is a barrier to treatment.

References (28)

  • M. Stitzer et al.

    Addict. Behav.

    (1979)
  • G.M. Robinson et al.

    Drug. Alcohol. Depend.

    (1993)
  • J. Strang

    Lancet

    (1985)
  • F.R. Goldman et al.

    Int. J. Addict.

    (1978)
  • T.F. Kirn

    JAMA

    (1988)
  • J.C. Ball et al.

    The Effectiveness of Methadone Maintenance Treatment

    (1991)
  • W.K. Bickel et al.

    Clin. Pharmacol. Ther.

    (1988)
  • R.E. Johnson et al.

    JAMA

    (1992)
  • L. Amass et al.

    NIDA Research Monograph no. 132, Problems of Drug Dependence 1992

  • W.K. Bickel et al.

    J. Pharmacol. Exp. Ther.

    (1988)
  • S.L. Walsh et al.

    NIDA Research Monograph no. 119 Problems of Drug Dependence 1991

  • M.J. Rance et al.
  • P.J. Fudala et al.

    Clin. Pharmacol. Ther.

    (1990)
  • Diagnostic and Statistical Manual of Mental Disorders (Third Edition, Revised)

    (1987)
  • Cited by (94)

    • Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers

      2015, Drug and Alcohol Dependence
      Citation Excerpt :

      A recent meta-analysis (Dunn et al., 2011) of 28 BUP treatment trials that culminated with outpatient dose tapering found that participant retention was modest (median: 65%, range: 4–100%), while urinalysis-verified opioid abstinence was low during maintenance treatment (median: 41%, range: 1–94%), at the end of dose tapering (median: 30%, range: 22–41%), and at a post-taper follow-up assessment (median: 23%, range: 8–52%). Several methodological factors were associated with better outcomes of BUP dose tapering: higher pre-taper BUP maintenance dose (16–32 mg/day vs. <16 mg/day; Fareed et al., 2012), longer BUP maintenance (median: 5 days; range: 0–56; Dunn et al., 2011), longer dose taper (median: 17 days; range: 0–120; Dunn et al., 2011) and opioid-abstinent contingent reinforcement (Amass et al., 1994; Becker et al., 2001; Marsch et al., 2005; Greenwald, 2008). In addition, pre-treatment opioid use-related characteristics have been found to predict BUP maintenance and dose taper response in treatment-seeking opioid dependent individuals; specifically, older age at onset of opioid use (Soyka et al., 2008), shorter duration of continuous opioid use (Soyka et al., 2008), less frequent opioid use (Ziedonis et al., 2009; Warden et al., 2012; Hillhouse et al., 2013) and non-injection opioid use (Subramaniam et al., 2011) were related to positive BUP outcome (opioid-negative urine at follow-up or greater treatment retention, depending on the study).

    • Treatment of opioid-dependent pregnant women: Clinical and research issues

      2008, Journal of Substance Abuse Treatment
      Citation Excerpt :

      In randomized double-blind studies, dose increases during the course of pregnancy for both methadone and buprenorphine were an average of three-unit increases (totaling averages of 30 mg for methadone and 6 mg for buprenorphine; Jones et al., 2005). Although there has been considerable research investigating the parameters of buprenorphine dosing in nonpregnant patients (e.g., Amass, Bickel, Crean, Blake, & Higgins, 1998; Amass, Bickel, Higgins, & Badger, 1994; Amass, Kamien, & Mikulich, 2000, 2001; Bickel, Amass, Crean, & Badger, 1999; Greenwald, Schuh, Hopper, Schuster, & Johanson, 2002; Petry, Bickel, & Badger, 2000, 2001), similar research has not yet been conducted in pregnant patients. Given the extended biological half-life buprenorphine by virtue of slow dissociation from the mu receptor, blood volume changes with pregnancy might be less problematic than with methadone maintenance.

    • Acute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: A case report and review

      2013, Pain Medicine (United States)
      Citation Excerpt :

      Additionally, buprenorphine dissociates slowly from mu-1 receptors [25], which accentuates this effect. These characteristics account for effective dosing as infrequently as every 48-hours [26,27,28]. There is insufficient data to determine an exact duration of action of buprenorphine, given its lipophilicity and depot-like action.

    View all citing articles on Scopus
    View full text